Sunday, October 4, 2026
26.5 C
Bengaluru

Executive Compensation in Pharma Companies in India: MNCs vs Indian Firms

The pharmaceutical industry in India is a rapidly evolving and high-growth sector, with executive compensation reflecting significant disparities between multinational corporations (MNCs) and homegrown Indian firms. With rising talent demands, innovation cycles, and global competitiveness, leadership pay structures have seen steady and notable increases in recent years. This blog provides an insightful overview of the executive pay landscape in India’s pharmaceutical companies, comparing MNCs with large Indian firms, and highlights key trends shaping compensation in 2025.

Salary Trends Since 2020

Since 2020, executive salaries across the pharma sector have risen approximately 9-10% annually, outpacing many other Indian industries. For example, Vice Presidents in pharma MNCs had an average salary of about ₹30 lakhs in 2020, which has climbed to ₹34–54 lakhs in 2025, with median pay around ₹38 lakhs. This reflects sector resilience underpinned by healthcare innovation and strong talent competition. 6figr+1​

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Why Is the World’s Pharmacy Failing to Protect Patients from Harm?

This MedicinMan Intelligence Report follows a disturbing trail—from Arun...

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

With over three decades of experience in the pharmaceutical...

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

India’s anaemia challenge is not simply about access to...

10 Years of Pharma M&A — Who’s Really Benefited?

Pharmaceutical M&A is usually discussed in the language of...

What’s Killing Patients? Cancer or Rigged Drug Prices?

The disease is real. So is the markup. Confusing...

Topics

Why Is the World’s Pharmacy Failing to Protect Patients from Harm?

This MedicinMan Intelligence Report follows a disturbing trail—from Arun...

10 Years of Pharma M&A — Who’s Really Benefited?

Pharmaceutical M&A is usually discussed in the language of...

What’s Killing Patients? Cancer or Rigged Drug Prices?

The disease is real. So is the markup. Confusing...

A Tale of Two Cities: Peptides and Prescriptions

What our health choices reveal about education, access and...

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

MedicinMan Intelligent Insights When Air India CEO Tewolde Gebremariam...
spot_img

Related Articles

spot_imgspot_img